Here are five developments in orthopedic regenerative medicine since July 11.

Orthopedic surgeon Ken Zaslav, MD, performed the first commercial case with CartiHeal's Agili-C in the U.S., the medtech company said July 26.

The CDC and FDA are investigating an outbreak of tuberculosis linked to recently recalled viable bone matrix material.

Ronald Hillock, MD, an adult joint reconstruction surgeon and musculoskeletal oncologist at Nevada Orthopedic & Spine Center in Las Vegas, connected with Becker's to answer, "Are orthobiologics overhyped?"

Gurtej Singh, MD, a physical medicine and rehabilitation physician, connected with Becker's to answer, "Are orthobiologics overhyped?"

Aziyo Biologics is recalling its viable bone matrix products after two patients were infected with Mycobacterium tuberculosis following surgeries, the orthobiologics company said July 13.

The first four surgeries using the EnFix RC fiber implant for rotator cuff repair were completed at Rush Oak Brook (Ill.) Surgery Center.

The Biden administration launched a program under the Advanced Research Projects Agency for Health focused on orthopedic tissue regeneration.

Here are five developments in orthobiologics to know since April 1:

Royal Biologics launched its Bio-Reign 3D bone graft substitute, the company said May 23.

Creative Medical Technology Holdings' StemSpine procedure was found to be effective in treating chronic lower back pain, according to a pilot study.

Bioventus sold its wound care segment to LifeNet Health, according to a May 10 news release.

OssDesign's Catalyst nanosynthetic bone graft has been used in 1,000 patients, the medtech company said May 9.

Bioventus' CEO Ken Reali left his post on April 4.

Aurora-based University of Colorado Medicine opened the CU Medicine Regenerative Medicine, Hand and Spine Center in Englewood.

Here are five updates in orthobiologics and regenerative medicine to know from the first quarter of 2023:

The world's first viable bone matrix that provides lineage-committed bone cells, LifeNet Health's ViviGen MIS, is now available for use in trauma procedures. 

Here are five updates in regenerative medicine since the end of December:

Orthobiologics company Royal Biologics has commercially launched a new platelet-rich plasma system, Bioincyte. 

A three-year study of Creative Medical Technology Holdings' StemSpine procedure found it was effective for addressing chronic lower back pain.